TY - JOUR
T1 - Implementing Buprenorphine Treatment in Community Settings in Australia
T2 - Experiences from the Buprenorphine Implementation Trial
AU - Lintzeris, Nicholas
AU - Ritter, Alison
AU - Panjari, Mary
AU - Clark, Nicolas
AU - Kutin, Jozica
AU - Bammer, Gabriele
PY - 2004
Y1 - 2004
N2 - Buprenorphine was registered in Australia as a maintenance and detoxification agent for the management of opioid dependence in November, 2000, and became widely available in August, 2001. This paper provides an overview of key developments in the introduction of buprenorphine treatment in Australia, with an emphasis upon the delivery of services in community-based (primary care) settings. A central study in this work was the Buprenorphine Implementation Trial (BIT), a randomized, controlled trial comparing buprenorphine and methadone maintenance treatment delivered under naturalistic conditions by specialist and community-based service providers (general practitioners and community pharmacists) in 139 subjects across nineteen treatment sites. In addition to conventional patient outcome measures (treatment retention, drug use, psychosocial functioning, and cost effectiveness), the BIT study also involved the development and evaluation of clinical guidelines, training programs for clinicians, and client literature, which are described here. Integration of treatment systems (methadone with buprenorphine, specialist and primary care programs) and factors thought to be important in the uptake of buprenorphine treatment in Australia since registration are discussed.
AB - Buprenorphine was registered in Australia as a maintenance and detoxification agent for the management of opioid dependence in November, 2000, and became widely available in August, 2001. This paper provides an overview of key developments in the introduction of buprenorphine treatment in Australia, with an emphasis upon the delivery of services in community-based (primary care) settings. A central study in this work was the Buprenorphine Implementation Trial (BIT), a randomized, controlled trial comparing buprenorphine and methadone maintenance treatment delivered under naturalistic conditions by specialist and community-based service providers (general practitioners and community pharmacists) in 139 subjects across nineteen treatment sites. In addition to conventional patient outcome measures (treatment retention, drug use, psychosocial functioning, and cost effectiveness), the BIT study also involved the development and evaluation of clinical guidelines, training programs for clinicians, and client literature, which are described here. Integration of treatment systems (methadone with buprenorphine, specialist and primary care programs) and factors thought to be important in the uptake of buprenorphine treatment in Australia since registration are discussed.
UR - http://www.scopus.com/inward/record.url?scp=2342513505&partnerID=8YFLogxK
U2 - 10.1080/10550490490440799
DO - 10.1080/10550490490440799
M3 - Review article
SN - 1055-0496
VL - 13
SP - S29-S41
JO - American Journal on Addictions
JF - American Journal on Addictions
IS - SUPPL. 1
ER -